A New Advancement in Erectile Dysfunction Treatment
WIKKON is pleased to announce that the National Medical Products Administration (NMPA) has officially approved the innovation product registration application for the E300.
Designed for the adjunctive treatment of mild to moderate vascular erectile dysfunction, the E300 represents an important milestone in the advancement of non-invasive erectile dysfunction treatment technologies in China.
The E300 system comprises a main unit — including a shock wave source, water treatment device, positioning frame, and trolley — together with a treatment head featuring a water balloon system and an optional foot switch.
The device uses low-intensity shockwaves applied to the penile area to stimulate angiogenesis and microvascular regeneration. By supporting improved blood flow and tissue repair, the E300 is designed to help improve erectile function and restore natural erectile mechanisms.
Key Highlights
- Domestic innovation product registration approved by the NMPA
- Effective adjunctive treatment of mild to moderate vascular erectile dysfunction
- Easy to operate, reducing the clinical burden on healthcare professionals
- Minimally invasive with few side effects, brings patient safety and comfort
- Helps reduce clinical treatment costs compared to surgical approaches
About WIKKON E300
E300 Erectile Dysfunction Shock Wave Therapy Device
The WIKKON E300 uses low-intensity extracorporeal shockwaves to stimulate angiogenesis and microvascular regeneration, improve penile blood engorgement, support tissue repair, and enhance erectile function.
Low-intensity extracorporeal shockwave therapy (Li-ESWT) is increasingly recognised as one of the most promising non-invasive treatment approaches for erectile dysfunction and has been referenced in both the American Urological Association (AUA) and European Association of Urology (EAU) guidelines for erectile dysfunction treatment.
The E300 incorporates WIKKON’s proprietary core technologies and holds multiple national innovation patents.
Clinical studies have also demonstrated that the E300 is both safe and effective in the treatment of erectile dysfunction, significantly improving erectile function, with a reported treatment efficacy rate of 67.5%*.
* Source：Wikkon internal data on file.
